{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:31:53Z","timestamp":1793442713651,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503542"],"award-info":[{"award-number":["82503542"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403670"],"award-info":[{"award-number":["82403670"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52473328"],"award-info":[{"award-number":["52473328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573342"],"award-info":[{"award-number":["82573342"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024B1515040006"],"award-info":[{"award-number":["2024B1515040006"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025 M772049"],"award-info":[{"award-number":["2025 M772049"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115441","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:04:16Z","timestamp":1791389056000},"page":"115441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Nucleus-targeted silencing of EPIC1 expression as an epigenetic strategy to modulate tumor immune microenvironment and potentiate cancer immunotherapy"],"prefix":"10.1016","volume":"399","author":[{"given":"Linzhuo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoding","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115441_bb0005","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115441_bb0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115441_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115441_bb0020","first-page":"844","article-title":"Pharmacological targeting of the cancer epigenome","volume":"5","author":"Mabe","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2026.115441_bb0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41467-022-35710-7","article-title":"Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation","volume":"14","author":"Lin","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115441_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115441_bb0035","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1016\/j.cell.2024.10.024","article-title":"Small and long non-coding RNAs: past, present, and future","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115441_bb0040","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics-challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115441_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2017.99","article-title":"Non-coding RNA networks in cancer","volume":"18","author":"Anastasiadou","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115441_bb0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","article-title":"Long noncoding RNAs in cancer pathways","volume":"29","author":"Schmitt","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115441_bb0055","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1126\/science.1231776","article-title":"Epigenetic regulation by long noncoding RNAs","volume":"338","author":"Lee","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115441_bb0060","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/cac2.12546","article-title":"Converting \"cold\" to \"hot\": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells","volume":"44","author":"Tang","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.jconrel.2026.115441_bb0065","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ccell.2018.03.006","article-title":"LncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer","volume":"33","author":"Wang","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115441_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.omto.2020.03.011","article-title":"Long non-coding RNA EPIC1 promotes cell proliferation and motility and drug resistance in glioma","volume":"17","author":"Wang","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.jconrel.2026.115441_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100563","article-title":"LncRNA EPIC1 promotes proliferation and inhibits apoptosis of gallbladder cancer cells by interacting with LET","volume":"26","author":"Fu","year":"2021","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115441_bb0080","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41588-018-0252-3","article-title":"Long noncoding RNA MALAT1 suppresses breast cancer metastasis","volume":"50","author":"Kim","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jconrel.2026.115441_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb3555","article-title":"LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance","volume":"7","author":"Guo","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115441_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adr9131","article-title":"The lncRNA EPIC1 suppresses dsRNA-induced type I IFN signaling and is a therapeutic target to enhance TNBC response to PD-1 inhibition","volume":"18","author":"Pattarayan","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jconrel.2026.115441_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115441_bb0100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/1541-7786.MCR-23-0282","article-title":"Exosomal lncRNA NEAT1 inhibits NK-cell activity to promote multiple myeloma cell immune escape via an EZH2\/PBX1 axis","volume":"22","author":"Wang","year":"2024","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115441_bb0105","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ncrna.2024.03.014","article-title":"Exosomal long non-coding RNAs in cancer: interplay, modulation, and therapeutic avenues","volume":"9","author":"Marima","year":"2024","journal-title":"Noncoding RNA Res."},{"key":"10.1016\/j.jconrel.2026.115441_bb0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41590-025-02355-9","article-title":"Long noncoding RNA regulation of immunity","volume":"27","author":"Yu","year":"2026","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115441_bb0115","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41556-019-0311-8","article-title":"Cellular functions of long noncoding RNAs","volume":"21","author":"Yao","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115441_bb0120","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202009045","article-title":"LNCcation: lncRNA localization and function","volume":"220","author":"Bridges","year":"2021","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115441_bb0125","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/nar\/gkv1206","article-title":"Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides","volume":"44","author":"Lennox","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115441_bb0130","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.omtn.2023.07.009","article-title":"Role of long non-coding RNAs in cancer: from subcellular localization to nanoparticle-mediated targeted regulation","volume":"33","author":"Wei","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115441_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115441_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-022-00975-3","article-title":"Targeting non-coding RNAs to overcome cancer therapy resistance","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115441_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008362","article-title":"RNAi therapies: drugging the undruggable","volume":"6","author":"Wu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115441_bb0150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.addr.2017.03.004","article-title":"Responsive nanocarriers as an emerging platform for cascaded delivery of nucleic acids to cancer","volume":"115","author":"Liu","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115441_bb0155","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.apsb.2024.09.009","article-title":"Advances and prospects of RNA delivery nanoplatforms for cancer therapy","volume":"15","author":"Attia","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.115441_bb0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115441_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115239","article-title":"Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release","volume":"207","author":"Liu","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115441_bb0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41392-022-01243-0","article-title":"Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115441_bb0175","first-page":"291","article-title":"Organelle-oriented nanomedicines in tumor therapy: targeting, escaping, or collaborating?","volume":"49","author":"Tan","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2026.115441_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2016.04.026","article-title":"Future of nanotherapeutics: targeting the cellular sub-organelles","volume":"97","author":"Ma","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115441_bb0185","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-020-00342-0","article-title":"Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting","volume":"5","author":"Fu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115441_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115411","article-title":"Precise subcellular targeting approaches for organelle-related disorders","volume":"212","author":"Shim","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115441_bb0195","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1021\/nn300571c","article-title":"Pegylated phospholipid micelles induce endoplasmic reticulum-dependent apoptosis of cancer cells but not normal cells","volume":"6","author":"Wang","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115441_bb0200","article-title":"Nucleus-specific RNAi nanoplatform for targeted regulation of nuclear lncRNA function and effective cancer therapy","volume":"2","author":"Huang","year":"2022","journal-title":"Exploration"},{"key":"10.1016\/j.jconrel.2026.115441_bb0205","article-title":"Remodeling of mitochondrial metabolism by a mitochondria-targeted RNAi nanoplatform for effective cancer therapy","volume":"20","author":"Xu","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.115441_bb0210","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.actbio.2024.12.061","article-title":"Nanoparticle-mediated efficient up-regulation of GSDMD-N to induce pyroptosis and enhance NK cell-based cancer immunotherapy","volume":"193","author":"Huang","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115441_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202314358","article-title":"Extracellular silica nanomatrices promote in vitro maturation of anti-tumor dendritic cells via activation of focal adhesion kinase","volume":"37","author":"Tam","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.115441_bb0220","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.actbio.2023.03.014","article-title":"Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy","volume":"162","author":"Huang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115441_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202500646","article-title":"Dual-responsive immunomodulatory RNAi nanoplatform for effective immune checkpoint blockade and enhanced cancer immunotherapy","volume":"14","author":"Cao","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.115441_bb0230","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115441_bb0235","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.apsb.2022.12.004","article-title":"Nanoparticles (NPs)-mediated lncBCMA silencing to promote eEF1A1 ubiquitination and suppress breast cancer growth and metastasis","volume":"13","author":"Yang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.115441_bb0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12943-025-02274-1","article-title":"Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis","volume":"24","author":"Huang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115441_bb0245","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.actbio.2025.08.001","article-title":"Nanoparticle-induced excessive mitophagy combined with immune checkpoint blockade for enhanced cancer immunotherapy","volume":"204","author":"Cao","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115441_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201802565","article-title":"Redox-responsive nanoparticle-mediated systemic RNAi for effective cancer therapy","volume":"14","author":"Xu","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.115441_bb0255","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymthe.2023.12.010","article-title":"Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity","volume":"32","author":"Luan","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115441_bb0260","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1038\/s41467-024-49989-1","article-title":"Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade","volume":"15","author":"von Roemeling","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115441_bb0265","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2026.115441_bb0270","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","article-title":"The Polycomb group protein EZH2 directly controls DNA methylation","volume":"439","author":"Vire","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115441_bb0275","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115441_bb0280","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115441_bb0285","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jconrel.2026.115441_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114545","article-title":"Biomimetic siRNA therapeutics attenuate mitochondrial DNA damage and cytokine storm in sepsis","volume":"390","author":"Jiang","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115441_bb0295","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7150\/thno.35568","article-title":"RNA nanotechnology-mediated cancer immunotherapy","volume":"10","author":"Lin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115441_bb0300","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.apsb.2025.02.020","article-title":"siRNA micelleplexes-mediated glutamine metabolism re-engineering for vascular normalization-boosted photo-immunotherapy","volume":"15","author":"Yi","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.115441_bb0305","first-page":"132","article-title":"Integrating siRNA targeting PKM2 with photodynamic therapy to induce tumor energy collapse","volume":"7","author":"Miao","year":"2026","journal-title":"Smart Mater. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600845X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600845X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:49:40Z","timestamp":1793440180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592600845X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":61,"alternative-id":["S016836592600845X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115441","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleus-targeted silencing of EPIC1 expression as an epigenetic strategy to modulate tumor immune microenvironment and potentiate cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115441"}}